Multiple myeloma treatment in newly diagnosed patients
The sponsor supports clinical research in newly diagnosed multiple myeloma among younger adults eligible for autologous stem cell transplantation, with interest in treatment strategies spanning induction, consolidation, and maintenance care.
- Autologous stem cell transplantation
- Induction therapy
- Consolidation therapy
- Maintenance treatment
These studies reflect a focus on sequencing therapies for plasma cell malignancies in transplant-eligible populations.
Relapsed/refractory multiple myeloma
Research activity also extends to relapsed/refractory multiple myeloma, including patients who have progressed after prior treatment and require new combination approaches.
- Relapse management
- Refractory disease
- Combination therapy
- Proteasome inhibitor-based regimens
The sponsor’s portfolio includes interest in improving disease control in heavily treated multiple myeloma.
Monoclonal antibody and antibody-drug conjugate therapy
The funded trials include therapies in monoclonal antibody and antibody-drug conjugate development for multiple myeloma, with attention to combining targeted agents with standard backbone treatments.
- Daratumumab
- Belantamab mafodotin
- Targeted combination regimens
- Toxicity profile
This area centers on therapeutic options designed for patients with persistent or returning disease.
Minimal residual disease and response assessment
Clinical research interests include minimal residual disease evaluation and deeper response monitoring in multiple myeloma, particularly using next generation sequencing to assess treatment effect.
- MRD negativity
- Next generation sequencing
- Progression-free survival
- Response monitoring
These topics are relevant to both post-transplant care and ongoing maintenance treatment.
